Logo
x

Search

Subscribe Now

Chronic Heart Failure

Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

  • July 22, 2021
Novartis's Entresto Receives US FDA's Approval for Chronic Heart Failure

Novartis's Entresto Receives US FDA's Approval for Chronic Heart Failure

  • February 17, 2021
AstraZeneca's Forxiga (dapagliflozin) Receives NMPA's Approval for Chronic Heart Failure

AstraZeneca's Forxiga (dapagliflozin) Receives NMPA's Approval for Chronic Heart Failure

  • February 5, 2021
Bayer and Merck's Verquvo (vericiguat) Receives the US FDA's Approval to Treat Chronic Heart Failure

Bayer and Merck's Verquvo (vericiguat) Receives the US FDA's Approval to Treat Chronic Heart Failure

  • January 21, 2021
AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for Chronic Heart Failure

AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for Chronic Heart Failure

  • November 30, 2020
Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic Heart Failure in China

Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic Heart Failure in China

  • August 28, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.